Teva Pharmaceutical Industries (TEVA) Amortization - Intangibles (2018 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Amortization - Intangibles for 9 consecutive years, with $22.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Amortization - Intangibles fell 47.62% year-over-year to $22.0 million; the trailing twelve-month figure through Jun 2026 stood at $126.0 million (down 53.85% YoY), and the FY2025 full-year result was $259.0 million, up 3.19% from the prior year.
• Amortization - Intangibles climbed to $22.0 million in Q2 2026 per TEVA's latest filing, from $8.0 million in the prior quarter.
• Across five years, Amortization - Intangibles topped out at $178.0 million in Q1 2023 and bottomed at $8.0 million in Q1 2026.
• Historically, Amortization - Intangibles has averaged $69.2 million across 5 years, with a median of $61.0 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Amortization - Intangibles soared 128.57% in 2025, then tumbled 93.39% in 2026.
• Over 5 years, Amortization - Intangibles stood at $132.0 million in 2022, then slumped by 53.79% to $61.0 million in 2023, then jumped by 34.43% to $82.0 million in 2024, then plunged by 60.98% to $32.0 million in 2025, then slumped by 31.25% to $22.0 million in 2026.
• According to Business Quant data, Amortization - Intangibles over the past three periods registered $22.0 million, $8.0 million, and $32.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.